Surgery Partners (SGRY)
(Delayed Data from NSDQ)
$33.69 USD
+5.05 (17.63%)
Updated Aug 23, 2024 03:59 PM ET
After-Market: $33.75 +0.06 (0.18%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth D Momentum C VGM
Surgery Partners (SGRY) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$39.67 | $50.00 | $31.00 | 38.51% |
Price Target
Based on short-term price targets offered by 12 analysts, the average price target for Surgery Partners comes to $39.67. The forecasts range from a low of $31.00 to a high of $50.00. The average price target represents an increase of 38.51% from the last closing price of $28.64.
Analyst Price Targets (12)
Broker Rating
Surgery Partners currently has an average brokerage recommendation (ABR) of 1.42 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 12 brokerage firms. The current ABR compares to an ABR of 1.42 a month ago based on 12 recommendations.
Of the 12 recommendations deriving the current ABR, nine are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 75% and 8.33% of all recommendations. A month ago, Strong Buy made up 75%, while Buy represented 8.33%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/SGRY.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 9 | 9 | 9 | 8 | 8 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 2 | 2 | 2 | 2 | 2 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.42 | 1.42 | 1.42 | 1.45 | 1.45 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/7/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
8/7/2024 | The Benchmark Company | William Sutherland | Strong Buy | Strong Buy |
8/7/2024 | Not Identified | Not Identified | Moderate Buy | Moderate Buy |
8/1/2024 | Cowen & Co. | Ryan Langston | Strong Buy | Strong Buy |
7/2/2024 | Cantor Fitzgerald & Co | Sarah James | Strong Buy | Strong Buy |
6/28/2024 | Macquarie Capital Securities | Tao Qiu | Not Available | Strong Buy |
5/7/2024 | SVB Securities | Whit Mayo | Strong Buy | Strong Buy |
3/6/2024 | Not Identified | Not Identified | Not Available | Hold |
11/8/2023 | Mizuho SecuritiesUSA | Ann K Hynes | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.42 |
ABR (Last week) | 1.42 |
# of Recs in ABR | 12 |
Average Target Price | $39.67 |
LT Growth Rate | 19.60% |
Industry | Medical Services |
Industry Rank by ABR | 148 of 253 |
Current Quarter EPS Est: | 0.27 |